Zinc — Full Portfolio
21 tracked investments · listed companies and verified rows first
Novai applies advanced molecular and computational approaches to eye disease, supporting clinicians and researchers in translating scientific findings into patient treatment options.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesReading, GB
Prof. Francesca Cordeiro(Founder, Director & Chief Executive Officer)Prof. M. Francesca Cordeiro(Founder & CEO)MARIA FRANCESCA CORDEIRO(Director)
BoardKARL DAVID KEEGAN(Director)STEPHEN ROY PAGE(Director)
Board seatNatalie Pankova· per SEC Form D · $1.1M raise · filed May 2023
Co-investorsAnglia Capital GroupExSight VenturesInBC Investment Corp.
Anocis is a pharmaceutical drug discovery company focused on early-stage development in neuroscience, particularly ion channel research.
AI & Machine LearningBiotechHealthtechMedical Devices
Dermott O'Callaghan(CSO)Andy McElroy(Acting CEO)
Clyde Hydrogen develops modular hydrogen production systems ranging from 100kW to 100MW+ for applications including emergency backup power, industrial energy storage, and mobility refueling.
CleantechDeep TechEnergyGlasgow, GB
Prof Mark Symes(CTO)Dr Matt Lees(CEO)Dr Jos Trehern(CSO)
Co-investorsOne Planet Capital
CO2Volt develops high-performance acidic CO₂ electrolysers that convert captured carbon dioxide into valuable chemicals, fuels, and industrial feedstocks.
CleantechClimate TechDeep TechLiverpool, GB
Alex Cowan(CTO)in
ionSIGHT provides an AI-driven analytical platform using native mass spectrometry to analyze protein structure and interactions for drug discovery applications.
AI & Machine LearningBiotechDeep Tech
Dr Rod Chalk(CEO)Dr Weston Struwe(CSO)Dr Mark van der Wilk(CTO)
Co-investorsOxford University Innovation
Neurolase develops AI-powered technology for brain surgery, aiming to improve surgical precision and patient outcomes in neurosurgery, particularly for brain tumor resection.
AI & Machine LearningDeep TechHealthtechMedical Devices
Monika Kott(Co-Founder & CEO)inBabar Vaqas(Co-Founder & CMO)in
Co-investorsOxford Technology Management
Serenatis Bio develops small-molecule drugs targeting glutamate and dopamine pathways to treat obsessive-compulsive disorder, a mental health condition with limited effective therapeutic options.
BiotechMental HealthCambridge, GB
Nick Sireau(Executive Chairman & Co-founder)inDavid Cavalla(CEO & Co-founder)in
Co-investorsP53 Invest
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AI & Enabling TechnologiesBioharvClinical ServicesComponents & MaterialsEngineering BiologyEngineering Process TechnologiesEnvironmentGreen Technology DevicesKilo GenLaser- and AI-powered surgical systemMedical DevicesMigrationSpeekTherapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.